公开(公告)号：EP1411046B1

公开(公告)日：2009-09-16

申请号：EP02738777.8

申请日：2002-06-21

申请人： Kirin Pharma Kabushiki Kaisha

发明人： FUJIWARA, Yasunari, c/o Kirin Beer K.K. ,  SENGA, Terufumi, c/o Kirin Beer K.K. ,  NISHITOBA, Tsuyoshi, c/o Kirin Beer K.K. ,  OSAWA, Tatsushi, c/o Kirin Beer K.K. ,  MIWA, Atsushi, c/o Kirin Beer K.K. ,  NAKAMURA, Kazuhide, c/o Kirin Beer K.K.

IPC分类号： C07D215/22 ,  C07D239/86 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/517 ,  A61K31/5377 ,  A61P35/00

CPC分类号： C07D215/233 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/517 ,  A61K31/5377 ,  C07D215/40 ,  C07D239/88 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12

摘要： A compound having strong antitumor activity. It is a compound represented by the formula (I) or a pharmaceutically acceptable salt or solvate of the compound: (I) [wherein X is CH or nitrogen; Z is oxygen or sulfur; L is oxygen or sulfur; M is CR10R11 (R10 and R11 each is hydrogen, alkyl, or alkoxy) or NR12 (R12 is hydrogen or alkyl); R1, R2, R3 each is hydrogen or optionally substituted alkoxy; R4 is hydrogen; R5 to R8 each is hydrogen, halogeno, alkoxy, etc.; and R9 is -R14, alkyl optionally substituted by -T-R15 or -NR16R17 (T is oxygen, sulfur, or NH; R14 is an optionally substituted carbon ring or heterocycle; and R15 to R17 each is alkyl or an optionally substituted carbon ring or heterocycle), -NR18R19 (R18 and R19 each is hydrogen, optionally substituted alkyl, or an optionally substituted carbon ring or heterocycle), or an optionally substituted carbon ring or heterocycle].

公开(公告)号：EP1354034B8

公开(公告)日：2008-06-18

申请号：EP01987182.1

申请日：2001-11-30

申请人： MEDAREX, INC. ,  Kirin Pharma Kabushiki Kaisha

发明人： TOMIZUKA, Kazuma ,  ISHIDA, Isao ,  LONBERG, Nils ,  HALK, Ed

IPC分类号： C12N15/00 ,  A01K67/027 ,  C12N5/06 ,  C07K16/00 ,  C12N5/20

CPC分类号： A01K67/0278 ,  A01K67/02 ,  A01K67/0276 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/072 ,  A01K2217/075 ,  A01K2217/15 ,  A01K2217/30 ,  A01K2227/105 ,  A01K2267/01 ,  A61K39/00 ,  A61K2039/505 ,  C07K14/70535 ,  C07K16/00 ,  C07K16/18 ,  C07K16/243 ,  C07K16/2812 ,  C07K16/2818 ,  C07K16/2863 ,  C07K2317/14 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/92 ,  C12N5/0635 ,  C12N5/163 ,  C12N15/8509 ,  C12N2015/8518 ,  C12P21/005 ,  C12Q1/6881 ,  C12Q2600/158

摘要： The present invention provides a transgenic nonhuman mammal, preferably a rodent, comprising two human immunoglobulin loci, wherein one of two said human immunoglobulin loci is a human heavy chain locus and the other locus is a human light chain locus; and wherein only one of said loci is of a transchromosome. In some transgenic nonhuman mammals, the endogenous mammalian heavy chain locus and at least one mammalian light chain locus are inactivated. In some such transgenic nonhuman mammals, the endogenous mammalian heavy chain locus and kappa light chain locus are inactivated. The present invention further provides methods of generating a plurality of B cells from a transgenic nonhuman mammal expressing human antibody sequences. Additional methods of the invention comprise fusing the plurality of B cells with immortalized cells to form hybridomas. The present invention also provides methods of generating a human sequence antibody from a transgenic nonhuman mammal.

摘要翻译： 本发明提供了包含两个人免疫球蛋白基因座的转基因非人哺乳动物，优选啮齿动物，其中两个所述人免疫球蛋白基因座中的一个是人重链基因座，另一个基因座是人轻链基因座; 并且其中只有一个所述基因座是转染色体。 在一些转基因非人类哺乳动物中，内源哺乳动物重链基因座和至少一个哺乳动物轻链基因座失活。 在一些这样的转基因非人类哺乳动物中，内源性哺乳动物重链基因座和κ轻链基因座失活。 本发明进一步提供了从表达人抗体序列的转基因非人哺乳动物产生多种B细胞的方法。 本发明的其他方法包括将多个B细胞与永生化细胞融合以形成杂交瘤。 本发明还提供了从转基因非人类哺乳动物产生人类序列抗体的方法。

公开(公告)号：EP1391511B1

公开(公告)日：2008-06-11

申请号：EP02769569.1

申请日：2002-05-10

申请人： Kirin Pharma Kabushiki Kaisha

发明人： KUROIWA, Yoshimi c/o Hematech,LLC ,  TOMIZUKA, Kazuma c/o Pharmaceutical Research Laboratories Kirin Beer ,  YOSHIDA, Hitoshi c/o GEMINI SCIENCE INC. ,  ISHIDA, Isao; Pharmaceutical Division, Kirin Beer

IPC分类号： C12N15/09 ,  A01K67/027 ,  C07K16/00 ,  C12P21/08

CPC分类号： A01K67/0278 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2217/054 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0381 ,  A61K48/00 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/243 ,  C07K2317/21 ,  C12N15/8509 ,  C12N15/87 ,  C12N15/90 ,  C12N2800/30

摘要： The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody lambda light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the non-human animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.

公开(公告)号：EP1847602A1

公开(公告)日：2007-10-24

申请号：EP06702685.6

申请日：2006-01-12

申请人： Kirin Pharma Kabushiki Kaisha

发明人： TAKAHASHI, Nobuaki c/o Kirin Beer Kabushiki Kaisha ,  YOSHIDA, Hideaki c/o Kirin Beer Kabushiki Kaisha

IPC分类号： C12N15/02 ,  A61K39/395 ,  A61P31/00 ,  A61P35/00 ,  A61P37/02 ,  C07K16/28 ,  C12P21/08

CPC分类号： C07K16/00 ,  C07K16/2878 ,  C07K2317/21 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/94

摘要： It is intended to provide highly stable variants of human antibody IgG2 and IgG3 subclasses. The present invention provides an IgG heavy chain comprising the constant region of a human IgG2 heavy chain having at least a substitution of Y for F at the 300th position, L for V at the 309th position, or A for T at the 339th position designated by the EU index of Kabat et al. and an IgG heavy chain comprising the constant region of a human IgG3 heavy chain having at least a substitution of K for N at the 392nd position or V for M at the 397th position designated by the EU index of Kabat et al. The present invention also provides monoclonal antibodies comprising these heavy chains.

摘要翻译： 旨在提供高度稳定的人抗体IgG2和IgG3亚类的变体。 本发明提供一种IgG重链，其包含人IgG2重链的恒定区，其具有在第300位具有至少取代F的F，在第309位具有至少取代F的L，在第309位具有至少替代F，或在第339位具有至少30 欧盟Kabat等指数 和包含人类IgG3重链的恒定区的IgG重链，其具有在Kabat等人的EU指数指定的第397位具有至少在第392位取代为K的N或V代表M的M。 本发明还提供了包含这些重链的单克隆抗体。

公开(公告)号：EP2258366A3

公开(公告)日：2012-01-18

申请号：EP10179308.1

申请日：2002-06-21

申请人： Kirin Pharma Kabushiki Kaisha

发明人： Fujiwara, Yasunari ,  Senga, Terufumi ,  Nishitoba, Tsuyoshi ,  Osawa, Tatsushi ,  Miwa, Atsushi ,  Nakamura, Kazuhide

IPC分类号： A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/517 ,  A61K31/5377 ,  C07D215/40 ,  C07D239/88 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12 ,  C07D215/233

CPC分类号： C07D215/233 ,  A61K31/47 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/517 ,  A61K31/5377 ,  C07D215/40 ,  C07D239/88 ,  C07D401/12 ,  C07D405/12 ,  C07D409/12 ,  C07D413/12

摘要： An objective of the present invention is to provide compounds having potent antitumor activity. The compounds of the present invention are represented by formula (I) or a pharmaceutically acceptable salt or solvate thereof:

公开(公告)号：EP2048229A1

公开(公告)日：2009-04-15

申请号：EP07768413.2

申请日：2007-07-06

申请人： Kirin Pharma Kabushiki Kaisha

发明人： KAKEDA, Minoru, c/o Kyowa Hakko Kirin Co.,Ltd. ,  TOMIZUKA, Kazuma, c/o Kyowa Hakko Kirin Co.,Ltd. ,  OSHIMURA, Mitsuo, c/o Tottori University ,  KAZUKI, Yasuhiro, c/o Tottori University

IPC分类号： C12N15/00 ,  A61K48/00 ,  A61P3/10 ,  A61P7/00 ,  A61P25/16 ,  C12N5/10 ,  C12N15/09 ,  C12P21/02

CPC分类号： C12N15/85 ,  A01K67/0275 ,  A01K2217/05 ,  A01K2217/206 ,  A01K2227/105 ,  A01K2267/03 ,  A61K38/00 ,  A61K48/00 ,  C12N2510/00 ,  C12N2800/208 ,  C12N2800/30

摘要： This invention relates to a human artificial chromosome (HAC) vector carrying a human chromosome-derived centromere, a subtelomere sequence, and a telomere sequence, to a human cell medicine or human cells comprising the HAC vector, to methods for preparing the HAC vector and human cells, and to methods for producing a therapeutic protein using the HAC vector.

摘要翻译： 本发明涉及携带人染色体衍生着丝粒，亚端粒序列和端粒序列的人类人造染色体（HAC）载体，其包含HAC载体的人类细胞药物或人类细胞，制备HAC载体的方法和 人细胞，以及使用HAC载体产生治疗性蛋白质的方法。

公开(公告)号：EP1081221B1

公开(公告)日：2008-10-29

申请号：EP99921196.4

申请日：1999-05-20

申请人： Kirin Pharma Kabushiki Kaisha

发明人： KOBAYASHI, Kazuo ,  TAKEUCHI, Makoto ,  IWAMATSU, Akihiko ,  YAMAMOTO, Kenji ,  KUMAGAI, Hidehiko ,  YOSHIDA Satoshi

IPC分类号： C12N9/14 ,  C12N15/55 ,  C12N15/63 ,  C12N1/19 ,  C12N9/24 ,  C12N9/80

CPC分类号： C12Y302/01096 ,  C12N9/2402

摘要： An endo-β-N-acetylglucosaminidase gene encoding the following protein (a) or (b): (a) a protein comprising an amino acid sequence represented by SEQ ID NO:3; and (b) a protein comprising an amino acid sequence derived from the amino acid sequence represented by SEQ ID NO:3 by deletion, substitution, insertion or addition of at least one amino acid and having the activity of endo-β-N-acetylglucosaminidase.

公开(公告)号：EP1970448A1

公开(公告)日：2008-09-17

申请号：EP08010546.3

申请日：2002-05-10

申请人： Kirin Pharma Kabushiki Kaisha

发明人： Kuroiwa, Yoshimi ,  Tomizuka, Kazuma ,  Yoshida, Hitoshi ,  Ishida, Isao

IPC分类号： C12N15/09 ,  A01K67/027 ,  C07K16/00 ,  C12P21/08

CPC分类号： A01K67/0278 ,  A01K67/0275 ,  A01K67/0276 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/052 ,  A01K2217/054 ,  A01K2217/15 ,  A01K2227/105 ,  A01K2267/01 ,  A01K2267/0381 ,  A61K48/00 ,  A61K2039/505 ,  C07K16/00 ,  C07K16/243 ,  C07K2317/21 ,  C12N15/8509 ,  C12N15/87 ,  C12N15/90 ,  C12N2800/30

摘要： The present invention relates to a human artificial chromosome which is genetically transmissible to the next generation with high efficiency and the method for using the same. More specifically, the present invention relates to: a human artificial chromosome in which an about 3.5 Mb to about 1 Mb region containing an antibody λ light chain gene derived from human chromosome 22 is bound to a chromosome fragment which is transmissible to a progeny through a germ line of a non-human animal, said chromosome fragment is derived from another human chromosome; a non-human animal carrying the human artificial chromosome and an offspring thereof; a method for producing the non-human animal; a method for producing a human antibody using the non-human animal or an offspring thereof; and a human antibody-producing mouse carrying the human artificial chromosome.

摘要翻译： 本发明涉及一种人类人工染色体所有这些是具有高效率和使用该方法的基因传播给下一代。 更具体地，本发明涉及：其中A人类人工染色体至约3.5 MB至约1Mb的区域在抗体包含“来源于人22号染色体衍生的轻链基因被结合到染色体片段所有这些是透射通过到一个子代 非人类动物的种系，所述染色体片段从另一个人染色体衍生的; 非人类动物携带人类人工染色体和其后代; 用于制造非人类动物的方法; 使用非人动物或它们的后代上生产人抗体的方法; 和产生人抗体的小鼠携带人类人工染色体。

公开(公告)号：EP1916300A1

公开(公告)日：2008-04-30

申请号：EP07001391.7

申请日：1996-08-29

申请人： Kirin Pharma Kabushiki Kaisha

发明人： Kazuma, Tomizuka c/o Kirin Pharma K.K. ,  Hitoshi, Yoshida c/o Kirin Pharma K.K. ,  Kazunori, Hanaoka c/o Kitasato Daigaku Rigaku-bu ,  Mitsuo, Oshimura c/o Tottori Daigaku ,  Isao, Ishida c/o Kirin Pharma K.K.

IPC分类号： C12N15/00 ,  A01K67/027 ,  C12N15/90 ,  C12N5/10 ,  C07K16/00 ,  C12N15/08 ,  C12N15/06 ,  C12N15/85

CPC分类号： A01K67/0275 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/01 ,  C07K16/00 ,  C07K16/18 ,  C12N15/8509 ,  C12N15/90 ,  C12N2517/02

摘要： A method for producing a chimeric non-human animal, which comprises preparing a microcell containing a foreign chromosome(s) or a fragment(s) thereof and transferring the foreign chromosome(s) or fragment(s) thereof into a pluripotent cell by fusion with the microcell. A chimeric non-human animal which can be produced by the above method and its progeny; tissues and cells derived therefrom; and a method for using the same. Further, a pluripotent cell containing a foreign chromosome(s) or a fragment(s) thereof, a method for producing the same, and a method for using the same are also provided.

摘要翻译： 一种嵌合非人动物的制备方法，其包括制备含有外来染色体或其片段的微细胞，并通过融合将其外源染色体或片段转移到多能细胞中 与微电池。 可以通过上述方法制备的嵌合非人动物及其后代; 从其衍生的组织和细胞; 及其使用方法。 此外，还提供了含有外来染色体或其片段的多能细胞，其制备方法及其使用方法。

公开(公告)号：EP1605039B1

公开(公告)日：2008-04-23

申请号：EP04716785.3

申请日：2004-03-03

申请人： Kirin Pharma Kabushiki Kaisha

发明人： SERIZAWA, Isao ,  YAMAGUCHI, Yasunori ,  EHARA, Hiromi

IPC分类号： C12N5/06 ,  C12N5/08 ,  A61K35/12 ,  A61P37/00 ,  A61P37/06 ,  A61P37/08

CPC分类号： C12N5/064 ,  A61K2035/122 ,  A61K2035/124 ,  C12N5/0639

摘要： The present invention relates to dendritic cell and cell mixture which is capable of suppressing T cell-dependent immune response specific for an antigen. The dendritic cell according to the present invention is a dendritic cell capable of suppressing T cell-dependent immune response specific for an antigen, which presents antigen fragment of said antigen which is presented against T cell in said immune response, and alpha-glycosylceramide derivative. The cell mixture according to the present invention is a cell mixture capable of suppressing T cell-dependent immune response specific for an antigen, which comprises dendritic cells presenting at least antigen fragment of said antigen which is presented against T cell in said immune response, and dendritic cells presenting at least alpha-glycosylceramide derivative.